論文・技術情報追加のお知らせ

1. Argatroban-Associated Adverse Events: An Analysis Based on FDA Adverse Event Reporting System (FAERS).

アルガトランで新規AEシグナル複数検出

対象DB：FAERS

2. Real-world pharmacovigilance of risperidone: Analysis based on FAERS reports from physicians and pharmacists.

リスペリドンで多様な未記載AE高シグナル検出

対象DB：FAERS

3. Drug-induced dermatomyositis: a pharmacovigilance study of the FDA adverse event reporting system.

FAERS解析でDM誘発薬の有意シグナル特定

対象DB：FAERS

4. A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy.

トリプタンで虚血性有害事象の有意シグナル検出

対象DB：FAERS

5. Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database.

イソトレチノインで未記載AEや重篤IMEs検出

対象DB：FAERS

6. Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025.

メチマゾールAE新規シグナル複数検出

対象DB：FAERS

7. Real-world pharmacovigilance analysis of depression associated with antineoplastic agents.

抗がん剤で抑うつ関連有害事象のシグナル多数

対象DB：FAERS

8. Glucose dysregulation signals in weight-neutral atypical antipsychotics: A pharmacovigilance-pharmacodynamic evaluation of FAERS data.

体重に影響しにくい薬でも糖代謝異常、5-HT2C関与示唆

対象DB：FAERS

9. Retrospective cohort study of ocular adverse reactions to systemic drugs: insights from a multi-country spontaneous reporting database.

FAERSで全身薬の眼障害信号141薬剤を同定

対象DB：FAERS

10. Based on the FDA Adverse Event Reporting System Database, a Study on Signal Mining of Adverse Events for Guanylate Cyclase-C Receptor Agonists.

GC-C作動薬でGI症状中心、尿・電解質異常も示唆

対象DB：FAERS

11. Safety assessment of voclosporin: a real-world disproportionality analysis of the FAERS database.

ボクロスポリンAEは高血圧・頭痛多発、治療中断も頻発

対象DB：FAERS

12. Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database.

第2世代ALK-TKIは肝毒性低、初代/新規で致死率高傾向

対象DB：FAERS

13. A real-world pharmacovigilance analysis of acute renal failure associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).

サクビトリル・バルサルタンで急性腎障害リスク、早期入院増加傾向

対象DB：FAERS

14. Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study.

HER2標的薬で心不全報告強、薬剤差あり

対象DB：CVAR,FAERS,JADER

15. Arrhythmic events pertinent with antidepressants: a Bayesian disproportional analysis mining the FDA Adverse Event Reporting System database.

SSRIで不整脈PV強、クエチアピン高リスク

対象DB：FAERS

16. Comparing adverse events of Saphnelo and Benlysta: A real-world observational study based on the FDA adverse event reporting system (FAERS) following STROBE guidelines.

アニフロ不良多様、ベリムマブは操作系AE中心

対象DB：FAERS

17. Exploring the relationship between atorvastatin and rosuvastatin use and respiratory, thoracic, and mediastinal disorders: A retrospective study.

スタチンで呼吸器障害リスク、発現時期差あり

対象DB：FAERS

18. Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series.

ICI関連ネフローゼ症候群、早期重症例に注意

対象DB：FAERS

19. Assessment of Adverse Events of Teplizumab: A Real-world Pharmacovigilance Study Based on the FDA Adverse Event Reporting System.

テプリズマブで皮膚等にAE、発現早期傾向

対象DB：FAERS

20. Real-world pharmacovigilance study on neonatal congenital anomalies associated with maternal drug exposure using the FDA Adverse Event Reporting System.

FAERSで母体薬物と先天異常のシグナル検出

対象DB：FAERS

21. A study on adverse drug events of PD-1/PD-L1 inhibitors in lung cancer treatment: a decade-long data mining.

PD-1/PD-L1でADE多様、死亡因子と時期差示唆

対象DB：FAERS

22. Sex differences in cardiotoxicity of anaplastic lymphoma kinase inhibitors: An analysis of the FDA Adverse Event Reporting System.

ALK-TKIで心毒性シグナル、女性で顕著

対象DB：FAERS

23. Immune checkpoint inhibitor-related gastrointestinal adverse events: a disproportionality analysis based on the FAERS database.

ICIでGI有害事象高頻度、特に抗CTLA-4

対象DB：FAERS

24. Gastrointestinal adverse events associated with Hedgehog pathway inhibitors: a disproportionality analysis.

HPIで味覚障害・舌炎・肝障害のシグナル検出

対象DB：FAERS

25. Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess.

DMARDで肺線維症信号、高齢でリスク増大

対象DB：FAERS

26. FDA-Approved Biologics for CRSwNP: A Five-Year Analysis of the FDA Adverse Event Reporting System.

CRSwNP生物学薬でSAE予測因子を特定

対象DB：FAERS

27. Venous thromboembolism events associated with tofacitinib in rheumatoid arthritis patients: a real-world study from FAERS database.

トファシチニブでVTE報告リスク増加示唆

対象DB：FAERS

28. Angioedema risk of thrombolytics: an integrated assessment using disproportionality analysis of the USFDA adverse event reporting system, case reviews and meta-analysis.

血栓溶解薬×RAAS阻害で血管浮腫リスク増大

対象DB：FAERS

29. Potential adverse events of fluoxetine: a real-world study based on the FAERS database.

フルオキセチンで妊娠・新生児有害事象が強いシグナル

対象DB：FAERS

30. Signal mining and risk analysis of olanzapine adverse events in the FAERS database.

オランザピンで新たな心血管リスク示唆

対象DB：FAERS

31. Quality of Reports on Drug Toxicity in Eudravigilance: A Safety Physician's Perspective.

EV個別症例報告の質低くシグナル検出阻害

対象DB：EudraVigilance

32. Immune checkpoint inhibitors and metabolic events: results from a European safety analysis.

抗PD-1で糖尿病報告増加、特に1型高頻度

対象DB：EudraVigilance

33. Fatal Outcomes in Use of Clozapine: A VigiBase Study of 6402 Women and 11,222 Men.

クロザピン若年女性で肺塞栓死が過剰リスク

対象DB：VigiBase

34. Neurological Adverse Events from COVID-19 Vaccination and It's Associated Factors in Burkina Faso: Analysis of Spontaneous Reports from the National Database of Pharmacovigilance from 2021 to 2023.

COVIDワクチン後の神経症状は頻発・概ね軽症

対象DB：VigiBase

35. Signal Detection of Drug-Drug Interactions Between Topical Vitamin D3 Analogs and Oral Thiazide Diuretics in Hypercalcemia: Analysis of the Japanese Drug Event Report Database.

外用D3＋サイアザイドで高Caリスク増加

対象DB：JADER

36. Association between early administration of mucoactive agents and in-hospital mortality in patients with pneumonia requiring mechanical ventilation: a nationwide cohort study.

粘液溶解薬早期投与で人工呼吸中肺炎死亡低下

対象DB：DPC

37. Impact of a national reimbursement policy on anti-osteoporosis medication prescription at discharge after hip-fracture surgery in Japan: an interrupted time-series analysis.

報酬加算で退院時骨粗鬆症治療が大幅増加

対象DB：DPC

38. Chronological and Biological Age in Predicting Outcomes of Older Patients in Neurosurgery.

5因子mFIは脳外科予後予測に有用、若年で顕著

対象DB：DPC

39. Determinants of length of stay after first admission for osteoporotic proximal femoral fracture in Japan.

大規模病院でOPFF入院期間が短縮傾向

対象DB：DPC

40. Biodiversity and childhood asthma: A nationwide retrospective birth cohort study in Japan.

淡水魚多様性と停滞水が小児喘息低減

対象DB：JMDC

41. Epidemiology and treatment patterns of urachal remnants in adult patients with omphalitis: a nationwide claims-based study in Japan.

臍炎成人で尿膜管遺残16%、若年男性多く手術頻繁

対象DB：JMDC

42. Use of Influenza Antivirals in Pandemic Response.

抗ウイルス薬活用へ進化、機動的研究が鍵

対象DB：CPRD

43. Factors associated with long-term opioid therapy discontinuation for people with chronic non-cancer pain in UK primary care: a population-based retrospective cohort study.

英国CNCPのL-TOT中止関連因子を同定

対象DB：CPRD

44. Child Body Mass Index and Health Care Costs in England.

英国小児の不健康体重で医療費増加、肥満最多

対象DB：CPRD

45. Comparing IPCW Models to Adjust for Informative Censoring During COVID-19 Using Data From the Clinical Practice Research Datalink.

ATの選択バイアスをIPCWで緩和示唆

対象DB：CPRD

46. Treatment Patterns and Healthcare Resource Utilization Among Patients with Obstructive Hypertrophic Cardiomyopathy in Japan: A Claims Database Study.

日本の閉塞性HCMでBB中心、変更・中止多い傾向

対象DB：DeSC